Champions Oncology Analyst Ratings
Champions Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 38.89% | Roth MKM | $9 → $7.5 | Maintains | Buy |
| 03/15/2021 | 196.3% | Roth Capital | $13.5 → $16 | Maintains | Buy |
| 11/18/2019 | 103.7% | Benchmark | → $11 | Initiates Coverage On | → Speculative Buy |
| 09/20/2019 | 71.3% | Roth Capital | → $9.25 | Initiates Coverage On | → Buy |
| 07/24/2019 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/22/2023 | 38.89% | 羅斯MKM | $9→$7.5 | 維護 | 買 |
| 03/15/2021 | 196.3% | 羅斯資本 | $13.5→$16 | 維護 | 買 |
| 2019年11月18日 | 103.7% | 基準 | →$11 | 開始承保 | →投機性買入 |
| 2019年09月20日 | 71.3% | 羅斯資本 | →$9.25 | 開始承保 | →購買 |
| 2019年07月24日 | - | 詹尼·蒙哥馬利·斯科特 | 評級下調 | 購買→中性 |
What is the target price for Champions Oncology (CSBR)?
冠軍腫瘤學(CSBR)的目標價格是多少？
The latest price target for Champions Oncology (NASDAQ: CSBR) was reported by Roth MKM on September 22, 2023. The analyst firm set a price target for $7.50 expecting CSBR to rise to within 12 months (a possible 38.89% upside). 1 analyst firms have reported ratings in the last year.
Roth MKM於2023年9月22日報道了冠軍腫瘤學(納斯達克：CSBR)的最新目標價。這家分析公司將目標價定為7.50美元，預計CSBR將在12個月內上漲至38.89%。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Champions Oncology (CSBR)?
冠軍腫瘤學(CSBR)的最新分析師評級是多少？
The latest analyst rating for Champions Oncology (NASDAQ: CSBR) was provided by Roth MKM, and Champions Oncology maintained their buy rating.
Roth MKM提供了對冠軍腫瘤學(納斯達克：CSBR)的最新分析師評級，冠軍腫瘤學維持了買入評級。
When is the next analyst rating going to be posted or updated for Champions Oncology (CSBR)?
冠軍腫瘤學(CSBR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Champions Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Champions Oncology was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與冠軍腫瘤公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。冠軍腫瘤學的最後一次評級是在2023年9月22日提交的，所以你應該預計下一次評級將在2024年9月22日左右的某個時候提供。
Is the Analyst Rating Champions Oncology (CSBR) correct?
分析師評級冠軍腫瘤學(CSBR)正確嗎？
While ratings are subjective and will change, the latest Champions Oncology (CSBR) rating was a maintained with a price target of $9.00 to $7.50. The current price Champions Oncology (CSBR) is trading at is $5.40, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的冠軍腫瘤學(CSBR)評級保持不變，目標價在9.00美元至7.50美元之間。冠軍腫瘤學(CSBR)目前的交易價格為5.40美元，超出了分析師的預測範圍。